Medical CommunicationsOncology Updates Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
Medical CommunicationsOncology Updates Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer
Approval BlogMedical CommunicationsOncology Updates Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer
Approval BlogMedical CommunicationsOncology Updates Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer
Approval BlogMedical CommunicationsOncology Updates Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors
Approval BlogMedical CommunicationsOncology Updates Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer
Approval BlogMedical CommunicationsOncology Updates Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC
FEATURED BLOGSFEATURED INSIGHTSMedical CommunicationsOncology Updates Cadence expands its medical communication offerings through KOL Connect®, a comprehensive KOL relationship management solution
FEATURED INSIGHTSMedical CommunicationsOncology Updates What will be the impact of the ACA on cancer treatment?